JP2016516692A - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤 Download PDF

Info

Publication number
JP2016516692A
JP2016516692A JP2016500961A JP2016500961A JP2016516692A JP 2016516692 A JP2016516692 A JP 2016516692A JP 2016500961 A JP2016500961 A JP 2016500961A JP 2016500961 A JP2016500961 A JP 2016500961A JP 2016516692 A JP2016516692 A JP 2016516692A
Authority
JP
Japan
Prior art keywords
tert
butoxy
mmol
dimethyl
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016500961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516692A5 (enExample
Inventor
ビー・ナラシムフル・ナイドゥ
マノジ・ペイテル
ケビン・ピース
ワン・ジョンギュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016516692A publication Critical patent/JP2016516692A/ja
Publication of JP2016516692A5 publication Critical patent/JP2016516692A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016500961A 2013-03-13 2014-03-10 ヒト免疫不全ウイルス複製の阻害剤 Pending JP2016516692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779589P 2013-03-13 2013-03-13
US61/779,589 2013-03-13
PCT/US2014/022405 WO2014164428A1 (en) 2013-03-13 2014-03-10 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2016516692A true JP2016516692A (ja) 2016-06-09
JP2016516692A5 JP2016516692A5 (enExample) 2017-04-13

Family

ID=50543303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500961A Pending JP2016516692A (ja) 2013-03-13 2014-03-10 ヒト免疫不全ウイルス複製の阻害剤

Country Status (6)

Country Link
US (1) US9663536B2 (enExample)
EP (1) EP2970301B1 (enExample)
JP (1) JP2016516692A (enExample)
CN (1) CN105189510B (enExample)
ES (1) ES2619708T3 (enExample)
WO (1) WO2014164428A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9932356B2 (en) 2014-02-12 2018-04-03 Viiv Healthcare Uk (No. 5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3105236B1 (en) 2014-02-12 2017-10-18 ViiV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
US9834566B2 (en) 2014-02-18 2017-12-05 VIIV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) * 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126758A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
PT3107913T (pt) 2014-02-19 2018-09-28 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9637501B2 (en) 2014-02-20 2017-05-02 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
CN110407674A (zh) * 2018-08-14 2019-11-05 重庆市化工研究院 4-烯丙氧基苯甲醇、合成方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033735A1 (en) * 2010-09-08 2012-03-15 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013025584A1 (en) * 2011-08-18 2013-02-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013134113A1 (en) * 2012-03-05 2013-09-12 Bristol-Myers Squibb Company Fused pyrimidines as inhibitors of immunodeficiency virus replication
WO2013134142A1 (en) * 2012-03-06 2013-09-12 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014028384A1 (en) * 2012-08-16 2014-02-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
MX2009001036A (es) 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
CA2681695A1 (en) 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
ATE541841T1 (de) 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
ES2402322T3 (es) 2007-11-15 2013-04-30 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
ES2463720T3 (es) 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
EP2640729B1 (en) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibitors of hiv replication

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033735A1 (en) * 2010-09-08 2012-03-15 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013025584A1 (en) * 2011-08-18 2013-02-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013134113A1 (en) * 2012-03-05 2013-09-12 Bristol-Myers Squibb Company Fused pyrimidines as inhibitors of immunodeficiency virus replication
WO2013134142A1 (en) * 2012-03-06 2013-09-12 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014028384A1 (en) * 2012-08-16 2014-02-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
US9663536B2 (en) 2017-05-30
WO2014164428A1 (en) 2014-10-09
US20160002263A1 (en) 2016-01-07
EP2970301A1 (en) 2016-01-20
CN105189510A (zh) 2015-12-23
EP2970301B1 (en) 2017-01-11
ES2619708T3 (es) 2017-06-26
CN105189510B (zh) 2017-05-17

Similar Documents

Publication Publication Date Title
US9580431B2 (en) Inhibitors of human immunodeficiency virus replication
JP2016516692A (ja) ヒト免疫不全ウイルス複製の阻害剤
AU2017290755B2 (en) Diazepinone derivatives and their use in the treatment of hepatitis B infections
JP6214657B2 (ja) ヒト免疫不全ウイルス複製阻害剤
US8791108B2 (en) Inhibitors of human immunodeficiency virus replication
CA3067944C (en) Bicyclic ketone compounds and methods of use thereof
JP2024150460A (ja) 治療用化合物
US9273067B2 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
JP2026506997A (ja) 大環状アルファ４ベータ７インテグリン阻害剤
CN105008369B (zh) 人类免疫缺陷病毒复制抑制剂
US9409922B2 (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
EP3152215A1 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
KR20180035908A (ko) 인간 면역결핍 바이러스 복제의 억제제로서의 이미다조피리딘 매크로사이클
HK40056262B (zh) 治疗性化合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170308

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181023